Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 195

1.

How badly did it hit? Self-assessed emotional shock upon prostate cancer diagnosis and psychological well-being: a follow-up at 3, 12, and 24 months after surgery.

Stinesen Kollberg K, Wilderäng U, Thorsteinsdottir T, Hugosson J, Wiklund P, Bjartell A, Carlsson S, Stranne J, Haglind E, Steineck G.

Acta Oncol. 2017 Mar 17:1-7. doi: 10.1080/0284186X.2017.1300320. [Epub ahead of print]

PMID:
28303734
2.

Expert consensus document: Semantics in active surveillance for men with localized prostate cancer - results of a modified Delphi consensus procedure.

Bruinsma SM, Roobol MJ, Carroll PR, Klotz L, Pickles T, Moore CM, Gnanapragasam VJ, Villers A, Rannikko A, Valdagni R, Frydenberg M, Kakehi Y, Filson CP, Bangma CH; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium..

Nat Rev Urol. 2017 Mar 14. doi: 10.1038/nrurol.2017.26. [Epub ahead of print] Review.

PMID:
28290462
3.

The drama of prostate cancer diagnostics.

Bratt O, Hugosson J, Klotz L, Gnanapragasam V.

Lancet Oncol. 2017 Mar;18(3):e132. doi: 10.1016/S1470-2045(17)30121-3. Epub 2017 Mar 2. No abstract available.

PMID:
28271865
4.

Impact of cause of death adjudication on the results of the European prostate cancer screening trial.

Walter SD, de Koning HJ, Hugosson J, Talala K, Roobol MJ, Carlsson S, Zappa M, Nelen V, Kwiatkowski M, Páez Á, Moss S, Auvinen A; ERSPC Cause of Death Committees..

Br J Cancer. 2017 Jan 3;116(1):141-148. doi: 10.1038/bjc.2016.378. Epub 2016 Nov 17.

PMID:
27855442
5.

Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis.

Carlsson SV, de Carvalho TM, Roobol MJ, Hugosson J, Auvinen A, Kwiatkowski M, Villers A, Zappa M, Nelen V, Páez A, Eastham JA, Lilja H, de Koning HJ, Vickers AJ, Heijnsdijk EA.

Cancer. 2016 Nov 15;122(21):3386-3393. doi: 10.1002/cncr.30192. Epub 2016 Jul 26.

PMID:
27459245
6.

Correlation between stage shift and differences in mortality in the European Randomised study of Screening for Prostate Cancer (ERSPC).

Bokhorst LP, Zappa M, Carlsson SV, Kwiatkowski M, Denis L, Paez A, Hugosson J, Moss S, Auvinen A, Roobol MJ.

BJU Int. 2016 Nov;118(5):677-680. doi: 10.1111/bju.13505. Epub 2016 May 20. No abstract available.

PMID:
27104278
7.

Prostate Specific Antigen and Prostate Cancer in Chinese Men Undergoing Initial Prostate Biopsies Compared with Western Cohorts.

Chen R, Sjoberg DD, Huang Y, Xie L, Zhou L, He D, Vickers AJ, Sun Y; Chinese Prostate Cancer Consortium.; Prostate Biopsy Collaborative Group..

J Urol. 2017 Jan;197(1):90-96. doi: 10.1016/j.juro.2016.08.103. Epub 2016 Sep 2.

PMID:
27593477
8.

Properties of the 4-Kallikrein Panel Outside the Diagnostic Gray Zone: Meta-Analysis of Patients with Positive Digital Rectal Examination or Prostate Specific Antigen 10 ng/ml and Above.

Vickers A, Vertosick EA, Sjoberg DD, Roobol MJ, Hamdy F, Neal D, Bjartell A, Hugosson J, Donovan JL, Villers A, Zappala S, Lilja H.

J Urol. 2017 Mar;197(3 Pt 1):607-613. doi: 10.1016/j.juro.2016.09.086. Epub 2016 Sep 28.

PMID:
27693450
9.

Preparedness for side effects and bother in symptomatic men after radical prostatectomy in a prospective, non-randomized trial, LAPPRO.

Derogar M, Dahlstrand H, Carlsson S, Bjartell A, Hugosson J, Axén E, Johansson E, Lagerkvist M, Nyberg T, Stranne J, Thorsteinsdottir T, Wallerstedt A, Haglind E, Wiklund P, Steineck G; LAPPRO steering committee..

Acta Oncol. 2016 Dec;55(12):1467-1476. Epub 2016 Aug 16.

PMID:
27684933
10.

Corrigendum re: "Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial" [Eur Urol 2016;70:566-73].

Bergdahl AG, Wilderäng U, Aus G, Carlsson S, Damber JE, Frånlund M, Geterud K, Khatami A, Socratous A, Stranne J, Hellström M, Hugosson J.

Eur Urol. 2017 Feb;71(2):e81. doi: 10.1016/j.eururo.2016.09.014. Epub 2016 Sep 20. No abstract available.

PMID:
27663047
11.

Design-corrected variation by centre in mortality reduction in the ERSPC randomised prostate cancer screening trial.

Hakama M, Moss SM, Stenman UH, Roobol MJ, Zappa M, Carlsson S, Randazzo M, Nelen V, Hugosson J.

J Med Screen. 2016 Aug 9. pii: 0969141316652174. [Epub ahead of print]

PMID:
27510947
12.

Reply from Authors re: Roderick C.N. van den Bergh, Declan G. Murphy, Henk G. van der Poel. Expectant Management for Prostate Cancer: Lessons from the Past, Challenges for the Future. Eur Urol 2016;70:767-8.

Godtman RA, Stranne J, Hugosson J.

Eur Urol. 2016 Nov;70(5):769-770. doi: 10.1016/j.eururo.2016.05.006. Epub 2016 Jul 7. No abstract available.

PMID:
27210462
13.

Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial.

Godtman RA, Holmberg E, Khatami A, Pihl CG, Stranne J, Hugosson J.

Eur Urol. 2016 Nov;70(5):760-766. doi: 10.1016/j.eururo.2016.03.048. Epub 2016 Apr 16.

PMID:
27090975
14.

Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study.

Carlsson S, Assel M, Ulmert D, Gerdtsson A, Hugosson J, Vickers A, Lilja H.

Eur Urol. 2017 Jan;71(1):46-52. doi: 10.1016/j.eururo.2016.03.026. Epub 2016 Apr 13.

PMID:
27084245
15.

Oncological and functional outcomes 1 year after radical prostatectomy for very-low-risk prostate cancer: results from the prospective LAPPRO trial.

Carlsson S, Jäderling F, Wallerstedt A, Nyberg T, Stranne J, Thorsteinsdottir T, Carlsson SV, Bjartell A, Hugosson J, Haglind E, Steineck G.

BJU Int. 2016 Aug;118(2):205-12. doi: 10.1111/bju.13444. Epub 2016 Mar 18.

PMID:
26867018
16.

Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial.

Grenabo Bergdahl A, Wilderäng U, Aus G, Carlsson S, Damber JE, Frånlund M, Geterud K, Khatami A, Socratous A, Stranne J, Hellström M, Hugosson J.

Eur Urol. 2016 Oct;70(4):566-573. doi: 10.1016/j.eururo.2015.12.006. Epub 2015 Dec 24.

PMID:
26724840
17.

The Effect of Start and Stop Age at Screening on the Risk of Being Diagnosed with Prostate Cancer.

Godtman RA, Carlsson S, Holmberg E, Stranne J, Hugosson J.

J Urol. 2016 May;195(5):1390-6. doi: 10.1016/j.juro.2015.11.062. Epub 2015 Dec 8.

PMID:
26678954
18.

Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening.

Auvinen A, Moss SM, Tammela TL, Taari K, Roobol MJ, Schröder FH, Bangma CH, Carlsson S, Aus G, Zappa M, Puliti D, Denis LJ, Nelen V, Kwiatkowski M, Randazzo M, Paez A, Lujan M, Hugosson J.

Clin Cancer Res. 2016 Jan 1;22(1):243-9. doi: 10.1158/1078-0432.CCR-15-0941. Epub 2015 Aug 19.

19.

Rule-based versus probabilistic selection for active surveillance using three definitions of insignificant prostate cancer.

Venderbos LD, Roobol MJ, Bangma CH, van den Bergh RC, Bokhorst LP, Nieboer D, Godtman R, Hugosson J, van der Kwast T, Steyerberg EW.

World J Urol. 2016 Feb;34(2):253-60. doi: 10.1007/s00345-015-1628-y. Epub 2015 Jul 10.

20.

Corrigendum to "Incidence of Prostate Cancer After Termination of Screening in a Population-based Randomised Screening Trial" [Eur Urol 2013;64:703-9].

Bergdahl AG, Holmberg E, Moss S, Hugosson J.

Eur Urol. 2015 Aug;68(2):e46. doi: 10.1016/j.eururo.2015.01.021. Epub 2015 Feb 4. No abstract available.

PMID:
26149731

Supplemental Content

Loading ...
Support Center